Fulcrum Therapeutics, Inc.
NASDAQ:FULC · NASDAQ Global Market
+$0.06 today
Vol 6.05M · Avg 1.78M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
-48.40%
Period High
$14.60
Period Low
$3.14
Latest
$3.70
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$890.61M
Omeros Corporation
NASDAQ:OMER
$746.62M
Neurogene Inc.
NASDAQ:NGNE
$498.58M
Ocugen, Inc.
NASDAQ:OCGN
$428.23M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$301.65M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$281.27M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$279.78M
Bicycle Therapeutics plc
NASDAQ:BCYC
$277.23M
ADC Therapeutics S.A.
NYSE:ADCT
$139.27M
What is the latest FULC filing?
The latest filing shown is 8-K dated Jun 11, 2026.
How many recent filings does FULC have?
Intrinsic Alpha currently shows 20 recent filings for FULC.
Explore More
Continue the stock analysis
Jump to another research area for this company.